Cantor Fitzgerald analyst Pablo Zuanic maintained a Buy rating on Tilray (NASDAQ:TLRY) on Tuesday, setting a price target of $19, which is approximately 38.69% above the present share price of $13.7.
Zuanic expects Tilray to post earnings per share (EPS) of -$1.36 for the third quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Tilray, with an average price target of $18.88.
The analysts price targets range from a high of $23 to a low of $13.55.
In its latest earnings report, released on 02/28/2021, the company reported a quarterly revenue of $153.64 million and a net profit of -$56.3 million. The company's market cap is $6.11 billion.
According to TipRanks.com, Cantor Fitzgerald analyst Pablo Zuanic is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.5% and a 48.10% success rate.
Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It also supplies cannabis products to patients in a number of countries spanning five continents through its subsidiaries in Australia, Canada and Germany and it produces medical cannabis in Canada and Europe. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.